西司他丁/亚胺培南/瑞来巴坦(Cilastatin Sodium/Imipenem/Relebactam) - 药物靶点：Enzymes x PBPs x β-lactamase_在研适应症：感染，医院获得性细菌性肺炎，呼吸机相关细菌性肺炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Cilastatin/imipenem/relebactam、Cilastatin/relebactam/imipenem、IMI/REL

+ [15]

靶点

Enzymes x PBPs x β-lactamase

作用方式

抑制剂

作用机制

酶抑制剂、PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、β-lactamase抑制剂(β-内酰胺酶抑制剂)

治疗领域

感染呼吸系统疾病泌尿生殖系统疾病+ [3]

在研适应症

感染医院获得性细菌性肺炎呼吸机相关细菌性肺炎+ [11]

非在研适应症

耐碳青霉烯类细菌感染

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme Corp.

Merck & Co., Inc.Merck Sharp & Dohme BV

+ [1]

非在研机构

Merck Sharp & Dohme LLC

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2019-07-16),

复杂腹腔感染复杂的尿路感染革兰氏阴性菌感染+ [1]

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)

登录后查看时间轴

结构/序列

分子式C12H19N3O5S

InChIKeyGSOSVVULSKVSLQ-JJVRHELESA-N

CAS号74431-23-5

查看全部结构式(3)

关联

16

项与西司他丁/亚胺培南/瑞来巴坦相关的临床试验

ChiCTR2300070223

/ SuspendedN/AIIT

An assessment of the Ceftolozane/Tazobactam and Imipenem/Relebactam activity in the hypervirulent Klebsiella pneumoniae

开始日期2023-05-01

申办/合作机构

北京大学第三医院（北京大学第三临床医学院）

NCT05561764

/ Terminated临床4期IIT

A Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem/Cilastatin/Relebactam During Treatment of Acute Pulmonary Exacerbations in Adolescent and Adult Patients With Cystic Fibrosis

There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex, a group of opportunistic multidrug resistant pathogens that commonly infect patients with CF. This study will determine the pharmacokinetics and tolerability of imipenem/cilastatin/relebactam in 16 adolescent and adult patients with CF acute pulmonary exacerbations at one of seven participating hospitals in the US, with exploratory aim of reporting relative percent increase in FEV1 from pre- to post-treatment and return to baseline FEV1 after treatment with imipenem/cilastatin/relebactam for acute pulmonary exacerbations due to P. aeruginosa in patients with CF. Patients will receive a 10-14 day course of imipenem/cilastatin/relebactam, dosed according to renal function every 6 hours over 30 mins, with or without adjunctive aminoglycoside or fluoroquinolone therapy per local hospital guidelines. Blood will be sampled during one dosing interval at steady-state (i.e. after at least 3 doses) to determine concentrations and pharmacokinetics of imipenem and relebactam. Relative change in pulmonary function will be assessed two weeks after end of therapy. Safety and tolerability will be assessed throughout the duration of the study.

开始日期2023-01-03

申办/合作机构

Hartford Hospital

[+6]

NCT05146154

/ Withdrawn临床4期IIT

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.

开始日期2023-01-01

申办/合作机构

University of Illinois

[+1]

100 项与西司他丁/亚胺培南/瑞来巴坦相关的临床结果

登录后查看更多信息

100 项与西司他丁/亚胺培南/瑞来巴坦相关的转化医学

登录后查看更多信息

100 项与西司他丁/亚胺培南/瑞来巴坦相关的专利（医药）

登录后查看更多信息

32

项与西司他丁/亚胺培南/瑞来巴坦相关的文献（医药）

2025-06-01·Infectious Diseases Now

Antimicrobial activity of new anti-Pseudomonas beta-lactam-beta-lactamase inhibitors against Pseudomonas aeruginosa respiratory isolates recovered during the study for Monitoring Antimicrobial Resistance Trends (SMART) program in France (2016–2022)

Article

作者: Pailhoriès, Hélène ; Eckert, Catherine ; Pierrat, Gautier ; Woerther, Paul-Louis ; Corvec, Stéphane ; Kempf, Marie ; Zins, Charlie ; Bourge, Xavier ; Boyer, Sophie ; Dahyot, Sandrine ; Chenouard, Rachel

OBJECTIVES:

To assess the susceptibility of ceftolozane/tazobactam (C/T) and comparators to Pseudomonas aeruginosa isolates recovered from respiratory-tract-infections (RTI) between 2016-2022 in the French SMART study.

METHODS:

Antibiotic susceptibility testing and minimum inhibitory concentrations (MICs) of 717 P.aeruginosa isolates collected in five French hospitals were determined and interpreted according to the EUCAST-2022 guidelines. P. aeruginosa isolates resistant (R) to imipenem and/or C/T were screened by PCR for extended-spectrum-β-lactamases (ESBLs), AmpC and carbapenemase genes. The identified genes were sequenced and the variants determined.

RESULTS:

All in all, 96.5 % of P. aeruginosa isolates were susceptible to C/T, comparable to the susceptibilities of meropenem-vaborbactam (MVB = 96.5 %), imipenem/relebactam (IMI/REL = 96.9 %) and ceftazidime-avibactam (C/A = 97.0 %). MIC₅₀ and MIC₉₀ for C/T were 0.5 and 2 mg/L respectively against the 717 isolates. Among the 242 isolates (33.7 %) resistant to at least one anti-Pseudomonas β-lactam, close to 90 % were susceptible to C/T, C/A, MVB and IMI/REL. Among the 80 isolates resistant to piperacillin-tazobactam, cefepime and ceftazidime, 76.3 % were susceptible to C/T and only IMI/REL and amikacin reached susceptibility exceeding 80 %. Among the 32 isolates resistant to imipenem and meropenem, susceptibility exceeding 60 % was observed only for IMI/REL, C/T, and C/A. For these strains, the MIC₅₀ of C/T was 2 mg/L, while that of C/A was at the resistance threshold (8 mg/L). IMI/REL had the strongest activity (72 %) against the 25 isolates resistant to C/T. Lastly, 53 imipenem and/or C/T-R isolates harbored a class C β-lactam (blaPDC) variant, and one of them also carried the bla_PER-1 gene and another, the bla_VIM-2 gene.

CONCLUSION:

C/T is a reliable treatment option in RTI caused by P. aeruginosa.

2025-05-01·Journal of Global Antimicrobial Resistance

Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam

Article

作者: Minucci, Rita ; Mularoni, Alessandra ; Conaldi, Pier Giulio ; Gallo, Alessia ; Monaco, Francesco ; Cona, Andrea ; Castelbuono, Salvatore ; Di Carlo, Daniele ; Vazzana, Roberta ; Vaiana, Claudia ; Cuscino, Nicola

OBJECTIVE:

In recent decades, the increasing prevalence of multidrug-resistant Klebsiella pneumoniae carbapenemase (KPC)-carrying K. pneumoniae (KPC-Kp) has become a worldwide public concern. Herein, we characterised a ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (MER/VAB) and imipenem/relebactam (IMI/REL)-resistant KPC-Kp strain isolated from a critically ill transplant patient.

METHODS:

Antimicrobial susceptibility testing and whole-genome sequencing (WGS) were conducted to characterise the strain at phenotypic and genotypic levels. Genomic DNA was sequenced using the Illumina platform. Bioinformatic analyses were used to investigate the genome sequences both for resistance and virulence features, and for the characterisation of plasmids.

RESULTS:

Phenotypic characterisation revealed that the KPC-Kp isolate was highly resistant to a wide range of antibiotics, including all β-lactam/β-lactamase inhibitor combinations such as CAZ/AVI, MER/VAB, IMI/REL and cefiderocol. WGS analysis showed that the isolate, belonging to the rare lineage ST661, contained several resistance and virulence genes. Among the resistance genes, we identified a new KPC variant within the mobile genetic element Tn4401-KPC-245-characterised by the insertion of nine amino acids (RAPNKDDYT) at position 263 as well as an amino acid change within the protein sequence, E274D, compared with KPC-3. Interestingly, the presence of mutations only in the bla_KPC gene and not in other β-lactamase coding genes strongly points to the role of KPC-245 in β-lactam/β-lactamase inhibitor combinations and cefiderocol resistance.

CONCLUSIONS:

In our study, by using WGS analysis on a clinical isolate, we identified a new bla_KPC variant within the Tn4401 transposon. Our results confirm the importance of continuous surveillance of multidrug-resistant K. pneumoniae in the clinical context.

2025-04-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)

Article

作者: Guo, Xiaodan ; Iamboliyska, Zlatka ; Losada, Maria ; Tang, Zhengang ; Sun, Fang ; Wei, Feng ; Koseoglu, Sandra ; Ding, Lianshu ; Zhu, Mingfen ; Chen, Luke Francis ; Young, Katherine ; Qu, Jieming ; Li, Junjie ; Du, Xiaoling ; Xiang, Peng ; Chen, Chang ; Zhou, Min ; Bruno, Christopher

OBJECTIVES:

Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).

METHODS:

In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days. The primary endpoint was 28-day all-cause mortality (ACM). Secondary endpoints were clinical response (CR), microbiological response (MR), and adverse event (AE) incidence.

RESULTS:

In the modified intention-to-treat population (N = 270 [IMI/REL: n = 134; PIP/TAZ: n = 136]), demographics and baseline characteristics were comparable between treatment groups. Most patients were from China. IMI/REL was noninferior to PIP/TAZ for 28-day ACM (11.2% vs 5.9%; adjusted difference [95% confidence interval]: 5.2% [-1.5 to 12.4]). Secondary outcomes were comparable between treatment groups, including favorable CR and MR. AEs resulting in death were generally consistent with pre-existing or underlying illness.

CONCLUSIONS:

IMI/REL met noninferiority criteria vs PIP/TAZ for 28-day ACM, and safety profiles were comparable. This trial could support the use of IMI/REL to treat adults with HABP/VABP, including regional use in China.

32

项与西司他丁/亚胺培南/瑞来巴坦相关的新闻（医药）

2025-07-09

·医药经济报

信诺维、正大天晴、诺华新药申报或获批，涉及肺炎、疟疾等

1.信诺维细菌性肺炎新药上市申请获受理7月9日，CDE官网公示，信诺维在研β-内酰胺类/β-内酰胺酶抑制剂（BL/BLI）复方制剂1类新药注射用亚胺培南西司他丁钠福诺巴坦（注射用亚胺西福）的上市申请（NDA）获受理。据公司资料，该药是全球首个针对三大碳青霉烯类耐药革兰阴性杆菌（CRO）具有广谱抗菌活性的BL/BLI复方制剂，拟用于治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎（HABP/VABP）。此次申报基于国际多中心Ⅲ期临床研究的积极结果。这项随机、双盲、阳性对照研究共纳入450例患者，结果显示：患者第14天全因死亡率达到预设主要终点；对碳青霉烯类耐药人群的临床治疗成功率和微生物清除率均优于对照组（注射用亚胺西瑞）；整体耐受性良好，安全性特征符合预期。2.正大天晴2款新药申报上市7月9日，CDE官网公示，正大天晴提交2款新药上市申请，1款为1类新药库莫西利胶囊，另一款为2.4类新药氟维司群注射液。根据公司资料，前者为新型周期蛋白依赖性激酶2、4和6（CDK2/4/6）抑制剂，对CDK2、CDK4、CDK6激酶有不同程度的抑制效果。研究结果显示，其增强的CDK2和CDK4抑制活性可能有助于在临床上克服目前CDK4/6抑制剂的耐药性问题。后者为雌激素受体下调剂。3.诺华婴儿疟疾药在瑞士获批近日，诺华宣布旗下疟疾新药Coartem Baby已在瑞士获上市许可，据悉，此为全球首个用于治疗婴儿和年幼儿童疟疾的药物。参与该药物联合评估的8个非洲国家预计也将迅速批准该治疗方案。该药为可溶解剂型，可溶于母乳。诺华表示，迄今为止，尚无获得批准的疟疾治疗药物适用于体重低于4.5公斤的婴儿，存在治疗空白。此前市面上的疟疾治疗药物仅在至少6个月大的儿童中经过临床测试，婴儿通常被排除在治疗试验之外。来源：CDE官网、企业官网编辑：范晓艳、李咏诗版式编辑：余远泽审校：马飞、张松多款原研药主动注销意欲为何？辉瑞、GSK等巨头转身投向新赛道5家药店被通报，8款药品被点名！国家医保局严打欺诈骗保胡善联、赖诗卿等专家畅谈创新药新政：双轨支付、价格协商、全链支持www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

临床3期

2025-07-09

·BioBAY

信诺维1类新药注射用亚胺西福申报上市获受理！

2025年7月8日，国家药品监督管理局（NMPA）正式受理BioBAY园内企业信诺维在研β-内酰胺类/β-内酰胺酶抑制剂（BL/BLI）复方制剂1类新药——注射用亚胺培南西司他丁钠福诺巴坦（注射用亚胺西福）的上市申请（NDA），受理号：CXHS2500074。该药物是全球首个针对三大碳青霉烯类耐药革兰阴性杆菌（CRO）具有广谱抗菌活性的BL/BLI复方制剂，拟用于治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎（HABP/VABP）。此次申报基于XNW4107-302国际多中心III期临床研究（Reitab Study）的积极结果。这项随机、双盲、阳性对照研究共纳入450例患者，结果显示：疗效显著：第 14 天全因死亡率达到预设主要终点优势突出：对碳青霉烯类耐药人群的临床治疗成功率和微生物清除率均优于对照组（注射用亚胺西瑞）安全性良好：整体耐受性良好，安全性特征符合预期*其相关研究结果计划在未来的学术会议或学术期刊上发表。注射用亚胺西福对世界卫生组织（WHO）认定的三大 “最严重威胁” 耐药菌同时有效：碳青霉烯类耐药鲍曼不动杆菌（CRAB）碳青霉烯类耐药肠杆菌目细菌（CRE）碳青霉烯类耐药铜绿假单胞菌（CRPA）细菌耐药是当前全球公共卫生领域的重大挑战。根据中国细菌耐药监测网（CHINET）数据显示，CRO检出率持续保持高位，且药物治疗选择少。信诺维自创立之初就专注解决这一未被满足的临床需求，福诺巴坦（XNW4107）较其他新型BLI（如阿维巴坦、瑞莱巴坦等）具有更广、更强的抑酶活性，能全面有效抑制革兰阴性菌常见的A、C、D类酶活性，尤其是CRAB所产的OXA-23酶和CRE所产的KPC酶和OXA-48酶等。乐美杰信诺维首席执行官此次国家药监局受理注射用亚胺西福的上市申请，标志着信诺维在抗感染领域取得重要突破。“以创新科技守护人类健康”是信诺维始终坚守的使命。我们将持续关注抗感染领域的未尽需求，积极配合监管部门的审评工作，推动这一重要创新药物早日获批上市，为临床提供更多优质治疗选择，共同守护国民健康。注射用亚胺西福上市申请获受理是公司发展的重要里程碑，作为自主研发的新型BL/BLI复方制剂，在HABP/VABP治疗领域，其有潜力成为目前市场上唯一广谱、对重大耐药菌具有强大抗菌活性的治疗药物，有望为中国HABP/VABP患者带来全新的治疗选择，或将显著改善临床治疗结局。▌文章来源：信诺维责编：于嘉敏审核：任旭推荐阅读研发动态丨赛纳思医疗：治疗梗阻性肥厚型心肌病的创新疗法获批进入创新器械“绿色通道”研发动态丨圣因生物：靶向CFB用于补体相关疾病的siRNA药物完成首例受试者给药研发动态丨海迈医疗：首个国产生物型人工血管FIM临床研究结果正式公布

临床3期上市批准

2025-07-09

·医药观澜

速递丨信诺维1类抗菌新药「注射用亚胺西福」申报上市

7月8日，信诺维宣布，中国国家药品监督管理局（NMPA）正式受理其在研β-内酰胺类/β-内酰胺酶抑制剂（BL/BLI）复方制剂1类新药——注射用亚胺培南西司他丁钠福诺巴坦（注射用亚胺西福）的上市申请（NDA）。该药物是一款针对三大碳青霉烯类耐药革兰阴性杆菌具有广谱抗菌活性的BL/BLI复方制剂，拟用于治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎（HABP/VABP）。据信诺维新闻稿介绍，注射用亚胺西福对世界卫生组织（WHO）认定的三大 “最严重威胁” 耐药菌同时有效：碳青霉烯类耐药鲍曼不动杆菌（CRAB）、碳青霉烯类耐药肠杆菌目细菌（CRE）、碳青霉烯类耐药铜绿假单胞菌（CRPA）。福诺巴坦（XNW4107）较其他新型BLI（如阿维巴坦、瑞莱巴坦等）具有更广、更强的抑酶活性，能全面有效抑制革兰阴性菌常见的A、C、D类酶活性，尤其是CRAB所产的OXA-23酶和CRE所产的KPC酶和OXA-48酶等。此次申报基于XNW4107-302国际多中心3期临床研究（Reitab Study）的积极结果。这项随机、双盲、阳性对照研究共纳入450例患者，结果显示：疗效显著：第 14 天全因死亡率达到预设主要终点；优势突出：对碳青霉烯类耐药人群的临床治疗成功率和微生物清除率均优于对照组（注射用亚胺西瑞）；安全性良好：整体耐受性良好，安全性特征符合预期。参考资料：[1]信诺维1类新药注射用亚胺西福申报上市获受理！From https://mp.weixin.qq.com/s/d34xkqY1RBnV7INk8CXE4w免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期微生物疗法

100 项与西司他丁/亚胺培南/瑞来巴坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	西司他丁/亚胺培南/瑞来巴坦	J01CR	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
感染	日本	MSD KK (Tokyo)	2021-06-23
医院获得性细菌性肺炎	美国	Merck Sharp & Dohme Corp.	2020-06-04
呼吸机相关细菌性肺炎	美国	Merck Sharp & Dohme Corp.	2020-06-04
菌血症	欧盟	Merck Sharp & Dohme BV	2020-02-13
菌血症	冰岛	Merck Sharp & Dohme BV	2020-02-13
菌血症	列支敦士登	Merck Sharp & Dohme BV	2020-02-13
菌血症	挪威	Merck Sharp & Dohme BV	2020-02-13
医院获得性肺炎	欧盟	Merck Sharp & Dohme BV	2020-02-13
医院获得性肺炎	冰岛	Merck Sharp & Dohme BV	2020-02-13
医院获得性肺炎	列支敦士登	Merck Sharp & Dohme BV	2020-02-13
医院获得性肺炎	挪威	Merck Sharp & Dohme BV	2020-02-13
呼吸机相关性肺炎	欧盟	Merck Sharp & Dohme BV	2020-02-13
呼吸机相关性肺炎	冰岛	Merck Sharp & Dohme BV	2020-02-13
呼吸机相关性肺炎	列支敦士登	Merck Sharp & Dohme BV	2020-02-13
呼吸机相关性肺炎	挪威	Merck Sharp & Dohme BV	2020-02-13
复杂腹腔感染	美国	Merck Sharp & Dohme Corp.	2019-07-16
复杂的尿路感染	美国	Merck Sharp & Dohme Corp.	2019-07-16
革兰氏阴性菌感染	美国	Merck Sharp & Dohme Corp.	2019-07-16
肾盂肾炎	美国	Merck Sharp & Dohme Corp.	2019-07-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
耐碳青霉烯类细菌感染	临床3期	-	Merck Sharp & Dohme LLC	2015-08-21
粒细胞减少性发热	临床2期	美国	Merck Sharp & Dohme Corp.	2021-09-14
血液肿瘤	临床2期	美国	Merck Sharp & Dohme Corp.	2021-09-14
恶性实体肿瘤	临床2期	美国	Merck Sharp & Dohme Corp.	2021-09-14
脓毒症	临床1期	美国	Merck Sharp & Dohme Corp.	2021-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03583333 (Phase III, Pubmed \| Int J Infect Dis)	临床3期	医院获得性细菌性肺炎 \| 呼吸机相关细菌性肺炎	270	Imipenem/cilastatin/relebactam (IMI/REL)	製壓觸鹽壓餘獵範積膚(夢鹽構廠鑰鑰構餘鏇簾) = Secondary outcomes were comparable between treatment groups, including favorable CR 糧製鏇顧醖構衊鏇簾窪 (選淵鬱構構簾蓋衊獵網 ) 更多	积极	2025-04-01
				Piperacillin/tazobactam (PIP/TAZ)
NCT04493151 (CTgov)	临床1期	脓毒症	8	Imipenem, Cilastatin and Relebactam	獵艱築憲鏇壓製齋鏇餘(鏇築衊齋窪鏇簾鏇襯築) = 範鬱鑰窪艱襯鹽夢鏇壓蓋積顧膚構繭築築繭積 (憲醖獵繭築製憲壓顧願, 6.52) 更多	-	2024-08-07
NCT04983901 (CTgov)	临床2期	恶性实体肿瘤 \| 血液肿瘤 \| 粒细胞减少性发热	100	Meropenem+Linezolid+Cefepime+Piperacillin-Tazobactam+Daptomycin+Vancomycin	淵選淵膚範鹽繭願鹹鏇(願夢廠獵齋憲網鑰蓋壓) = 鑰壓築淵壓齋製構簾鏇鏇顧夢齋醖簾選艱積築 (衊糧鑰憲膚積選糧膚觸, 製製鑰選獵壓觸繭鏇繭 ~ 廠蓋獵鹹選鑰蓋衊窪鹽) 更多	-	2024-03-12
NCT03230916 (7655A-020, Pubmed \| J Clin Pharmacol)	临床1期	革兰氏阴性菌感染	46	Imipenem/cilastatin/relebactam	壓糧繭憲夢鏇艱網壓顧(餘齋窪積淵顧簾壓夢鑰) = 窪齋壓鏇構膚鬱築鬱觸築齋醖襯夢繭願衊糧獵 (鏇襯醖繭鑰積廠構構窪 ) 更多	-	2023-08-10
NCT03583333 (MK-7655A-016 \| 7655A-016 \| Phase III, CTgov)	临床3期	医院获得性细菌性肺炎 \| 呼吸机相关细菌性肺炎	274	IMI/REL FDC+Linezolid (IMI/REL FDC)	鑰衊襯糧壓願鬱艱艱淵 = 艱壓襯淵膚夢鬱遞蓋艱夢網鑰遞廠醖壓窪餘鑰 (餘夢鏇網網廠醖遞顧簾, 憲餘醖壓醖蓋積顧顧膚 ~ 壓憲糧築衊積製選艱獵) 更多	-	2023-06-28
				Linezolid+PIP/TAZ FDC (PIP/TAZ FDC)	鑰衊襯糧壓願鬱艱艱淵 = 築獵顧鏇鏇憲糧獵襯製夢網鑰遞廠醖壓窪餘鑰 (餘夢鏇網網廠醖遞顧簾, 鬱襯壓衊夢顧簾餘構糧 ~ 選鏇範艱鬱壓衊壓鏇簾) 更多
NCT02452047 (7655A-013 \| RESTORE-IMI 1, Pubmed \| Clin Infect Dis) 人工标引	临床3期	细菌感染	47	imipenem/relebactam	鬱積齋衊觸願夢憲淵製(蓋簾膚醖網鬱顧鏇選夢) = 鹹網構積積觸憲窪襯觸蓋廠築鹽窪網艱願襯鹽 (衊壓夢繭鬱鏇觸廠壓範 ) 更多	积极	2020-04-15
				imipenem+colistin	鬱積齋衊觸願夢憲淵製(蓋簾膚醖網鬱顧鏇選夢) = 鬱觸構築製窪觸積憲鏇蓋廠築鹽窪網艱願襯鹽 (衊壓夢繭鬱鏇觸廠壓範 ) 更多
NCT03293485 (7655A-017, CTgov)	临床3期	复杂腹腔感染 \| 复杂的尿路感染	83	imipenem+relebactam+cilastatin (cIAI/cUTI)	夢廠壓夢簾遞艱淵壓構 = 鹽壓鏇積觸構醖廠糧鏇襯艱觸蓋壓齋廠製選餘 (艱壓窪鏇範顧襯築構糧, 顧醖網簾窪製鑰製憲遞 ~ 糧網齋構鬱醖鏇遞選鑰) 更多	-	2019-09-17
				imipenem+relebactam+cilastatin (cIAI)	夢餘鹽範鑰獵鹹壓糧夢 = 鏇窪鑰襯襯鏇觸製簾網構醖製積襯蓋選壓鹹壓 (網鹹夢餘獵製齋鹽獵簾, 窪襯鏇構鹹蓋觸鏇範鑰 ~ 簾製選顧壓艱鬱糧夢壓) 更多
NCT02452047 (7655A-013 \| RESTORE-IMI 1, CTgov)	临床3期	耐碳青霉烯类细菌感染	50	Placebo to CMS+Imipenem+Cilastatin/Relebactam (Group 1: Imipenem+Cilastatin/Relebactam)	築選蓋壓鹹獵壓遞鏇鬱 = 選淵壓鏇構廠築鹹艱鹹衊構範憲齋網餘製衊蓋 (襯襯簾壓憲繭襯膚鹹壓, 膚淵醖齋襯積顧網窪獵 ~ 築餘構構夢蓋廠淵簾選) 更多	-	2018-10-19
				Imipenem+Cilastatin+Colistimethate sodium (CMS) (Group 2: Colistimethate Sodium + Imipenem+Cilastatin)	築選蓋壓鹹獵壓遞鏇鬱 = 繭顧鹹網願製鏇艱鹽網衊構範憲齋網餘製衊蓋 (襯襯簾壓憲繭襯膚鹹壓, 願築構憲遞淵構壓衊獵 ~ 鹹積遞壓選遞衊衊鑰夢) 更多